TNFRSF4 and neoplasm: Considering the important role of Treg depletion in the anti-tumor effect of OX40 antibodies, we hypothesized that ADCC-enhanced OX40 antibodies may have stronger clinical efficacy than non-ADCC-enhanced OX40 antibodies.